In the original paper, an AD subgroup called C2 or neuroendocrine expression type, was claimed to have a less favorable survival compared to the rest of the AD and that one gene, kallikrein 11 (KLK11) could separate this group from the rest of the tumors (6). The gene discussed is KLK11; the disease is Alzheimer disease.